Last update 01 Nov 2024
Innorna Co. Ltd

Innorna Co. Ltd

Private Company|
2019|
Guangdong Sheng, China
|
www.innorna.com

Overview

Tags

Infectious Diseases
Skin and Musculoskeletal Diseases
Respiratory Diseases
mRNA vaccine
Prophylactic vaccine
mRNA

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Infectious Diseases7
Endocrinology and Metabolic Disease1
Nervous System Diseases1
Top 5 Drug TypeCount
mRNA vaccine7
Prophylactic vaccine3
mRNA2
Top 5 TargetCount
BSEP(ATP binding cassette subfamily B member 11)1
CBS(cystathionine beta-synthase)1

Related

9
Drugs associated with Innorna Co. Ltd
COVID-2019 vaccine (InnoRNA)
Target-
Mechanism
Immunostimulants
Active Org.
Innorna Co. LtdInnorna Co. Ltd
Originator Org.
Innorna Co. LtdInnorna Co. Ltd
Active Indication
COVID-19
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
IN-006
Target-
Mechanism
Immunostimulants
Active Org.
Innorna Co. LtdInnorna Co. Ltd
Originator Org.
Innorna Co. LtdInnorna Co. Ltd
Active Indication
Respiratory Syncytial Virus Infections
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
IN-001(InnoRNA)
Target-
Mechanism
Immunostimulants
Active Org.
Innorna Co. LtdInnorna Co. Ltd
Originator Org.
Innorna Co. LtdInnorna Co. Ltd
Active Indication
Herpes Zoster
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
4
Clinical Trials associated with Innorna Co. Ltd
NCT06645665 / Not yet recruitingPhase 1
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006) in Healthy Adult Aged 18 Years and Above
NCT06287450 / Not yet recruitingPhase 1
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006) in Healthy Adult Participants
NCT06375512 / RecruitingPhase 1
A Phase 1, Randomized, Multicenter, Double-blind, Dose-ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants 50 to 69 Years Old
100 Clinical Results associated with Innorna Co. Ltd
Login to view more data
0 Patents (Medical) associated with Innorna Co. Ltd
Login to view more data
100 Deals associated with Innorna Co. Ltd
Login to view more data
100 Translational Medicine associated with Innorna Co. Ltd
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
1
5
Preclinical
Phase 1 Clinical
3
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
IN-001(InnoRNA)
Herpes Zoster
More
Phase 1
IN-006
Respiratory Syncytial Virus Infections
More
Phase 1
COVID-2019 vaccine (InnoRNA)
COVID-19
More
Phase 1
HSV(INNORNA)
Herpesviridae Infections
More
Preclinical
HMPV(INNORNA)
Metapneumovirus infection
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free